Allogene Therapeutics, Inc. (ALLO): Total Assets
$415.90M
As of 2025-12-31
$550.09M
As of 2026-06-30
-20.3%
3-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $415.90M | -24.2% | 2026-03-12, Balance as of period end |
| 2024-12-31 | $548.71M | -14.6% | 2026-03-12, Balance as of period end |
| 2023-12-31 | $642.84M | n/a | 2025-03-13, Balance as of period end |
| 2023-09-30 | $713.41M | n/a | 2024-03-14, Balance as of period end |
| 2023-06-30 | $773.01M | n/a | 2024-03-14, Balance as of period end |
| 2023-03-31 | $750.13M | n/a | 2024-03-14, Balance as of period end |
| 2022-12-31 | $821.58M | n/a | 2024-03-14, Balance as of period end |
| 2022-09-30 | $894.48M | n/a | 2024-03-14, Balance as of period end |
| 2022-06-30 | $955.62M | n/a | 2024-03-14, Balance as of period end |
| 2022-03-31 | $978.09M | n/a | 2024-03-14, Balance as of period end |
| 2021-12-31 | $1.05B | n/c | 2024-03-14, Balance as of period end |
| 2020-12-31 | $1.23B | +71.1% | 2022-02-23, Balance as of period end |
| 2019-12-31 | $717.80M | -7.2% | 2021-02-25, Balance as of period end |
| 2018-12-31 | $773.86M | n/a | 2020-02-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | 2025-12-31 | $415.90M | -24.2% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $186.08M | +11.8% |
| Amgen Inc (AMGN) | 2025-12-31 | $90.59B | -1.4% |
| Repligen Corp (RGEN) | 2025-12-31 | $2.95B | +4.2% |
| Champions Oncology, Inc. (CSBR) | 2026-04-30 | $26.99M | -16.6% |
| Bio-Techne Corp (TECH) | 2026-06-30 | $2.59B | +1.1% |
| Biogen Inc. (BIIB) | 2025-12-31 | $29.44B | +5.0% |
| Lineage Cell Therapeutics, Inc. (LCTX) | 2025-12-31 | $112.58M | -0.6% |
| Gilead Sciences, Inc. (GILD) | 2025-12-31 | $59.02B | 0.0% |
Compare ALLO, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗